Tirzepatide Research Overview: Dual Agonism, Trial Designs and Lot Records

Tirzepatide is the most clinically established compound in this Journal. Where the BPC-157 research overview deals with a preclinical literature, and the retatrutide research overview with an investigational one, tirzepatide has approved products and years of published trials. That makes the line between an approved medicine and research material more important, not less. For any individual batch, the analytical side lives in the LIV More Lot Passport, where each lot’s purity, amount, test date and certificate are filed against the lot number printed on the vial.

All three profiles are listed in the Journal archive.

Every finding below is labeled by study type, and no study amounts or outcome figures are restated.

What tirzepatide is

Tirzepatide is a linear peptide of 39 residues, built on the sequence of the native hormone GIP and engineered with non-coded amino acids. A C20 fatty diacid side chain is attached to the peptide through a linker. In this class of molecule, a lipid side chain of that kind is used to extend circulating half-life through reversible binding to albumin. Its PubChem record gives the molecular formula C225H348N48O68 and a molecular weight of about 4813.

The molecule was described in a 2018 discovery paper in Molecular Metabolism written by scientists at Eli Lilly and Company, its developer. Early papers use the code LY3298176, and later papers use the name tirzepatide.

These distinctions have practical weight. The formula and mass in a public record describe the free peptide, so a certificate has to state which form its measured values refer to.

How tirzepatide acts at two receptors

Tirzepatide is a dual agonist, but its two actions are not equal. A 2020 study in JCI Insight by Willard and colleagues calculated receptor occupancy and found greater engagement of the GIP receptor than of the GLP-1 receptor. The authors called the profile imbalanced.

The same study examined signaling in cell lines and primary islets. At the GIP receptor, tirzepatide behaved much like native GIP. At the GLP-1 receptor, it favored cyclic AMP generation over β-arrestin recruitment and drove less receptor internalization than native GLP-1. The authors described this as biased agonism.

For analysts, the working point is that “dual agonist” is shorthand. The measured profile is unequal across the two receptors and pathway-specific at one of them, and how those cellular properties relate to effects in a whole organism remains a research question.

What published tirzepatide research examines

The record follows the usual path for a drug candidate, from cells and mice to phase 3 programs. Each item below names the design and what was measured.

• In vitro, animal model and phase 1. The discovery paper characterized signaling in cell lines expressing incretin receptors and measured body weight, food intake, insulin secretion and glycemic profiles in mice. Its phase 1 program combined single and multiple ascending dose studies in healthy participants with a proof of concept study in type 2 diabetes, using dulaglutide as a positive control. The primary objective was safety and tolerability.
• Phase 3, type 2 diabetes, placebo-controlled. SURPASS-1 was a 40-week, double-blind, randomized, placebo-controlled trial of tirzepatide as monotherapy in people not previously treated with injectable diabetes therapy. The primary endpoint was change in HbA1c at 40 weeks.
• Phase 3, type 2 diabetes, active comparator. SURPASS-2 was a 40-week, open-label trial comparing tirzepatide with semaglutide, a selective GLP-1 receptor agonist. The primary end point was change in glycated hemoglobin at 40 weeks.
• Phase 3, obesity. SURMOUNT-1 was a 72-week, double-blind, randomized, placebo-controlled trial in adults with obesity, or with overweight plus a weight-related condition, and excluded people with diabetes. Its coprimary end points were based on change in body weight. A three-year analysis followed participants who also had prediabetes for 176 weeks on treatment plus a 17-week off-treatment period, with onset of type 2 diabetes as a key secondary end point.
• Phase 3, obstructive sleep apnea. SURMOUNT-OSA comprised two 52-week, double-blind, randomized, placebo-controlled trials in adults with obesity and moderate to severe sleep apnea, split by whether participants used positive airway pressure therapy. The primary end point was change in the apnea-hypopnea index.

Every trial above was funded by the developer, and the conclusions belong to the authors and sponsor of each paper.

What the tirzepatide record does not establish

Approval settles questions about specific products. It leaves others open, and it does not transfer to anything outside those products.

• Approval is product-specific. The FDA approved Mounjaro for type 2 diabetes in 2022 and Zepbound for chronic weight management in 2023, and in December 2024 it added obstructive sleep apnea to Zepbound’s indications. Each approval covers a defined product, its manufacturing, its labeling and its indicated population.
• Research material is not an approved drug. Material supplied for laboratory research shares a name with those products and nothing else. It is not made, tested, labeled or supplied under their approvals.
• Trial findings belong to the trial product. Each trial studied a pharmaceutical product given under protocol with medical oversight. Its results say nothing about any other material.
• Mechanism remains open. Imbalance and bias were measured in engineered cells, islets and occupancy models. How much of the clinical profile they explain is still being studied.
• One sponsor. The foundational trials were funded by the developer. That is normal for a drug candidate, and it is worth knowing when reading them.

Regulatory context shapes how any of this can be written. The FDA has warned companies that sold unapproved tirzepatide products directly to consumers for human use, with dosing instructions, while labeling them for research purposes. Under 21 CFR 201.128, intended use is judged by the objective intent of the people responsible for an article, as shown through labeling claims, advertising and the circumstances of distribution. A label alone does not decide it. The Journal therefore describes study designs and measurements and stops there, and it restates no doses or outcome figures from any trial.

Reading a certificate for a tirzepatide lot

A certificate of analysis is the document that ties a physical vial to analytical data. The specifications of an approved drug product do not apply to research material, so a research lot’s certificate is the only analytical record that describes it.

Identity by mass is the first check. A molecule of about 4.8 kDa appears in electrospray spectra as several charge states at once, so the certificate should say whether the reported mass is a deconvoluted value and whether it refers to the free peptide or a salt form. HPLC purity is the second. The lipid side chain makes the molecule strongly retained on reversed-phase columns, and related impurities can include deletion sequences and variants of the side chain or linker, so the chromatogram for the same lot matters as much as the percentage. Amount is the third, and it should be read from the lot’s own record.

• Lot number on the certificate matches the vial label
• Stated form names the peptide and any counterion
• Observed mass agrees with the expected mass, stated as deconvoluted or as a named ion
• HPLC result and chromatogram are attached for the same lot
• Peptide content, if reported, is kept separate from HPLC purity
• Stated amount per vial matches the label on that lot
• Testing laboratory and test date are identified

The research use policy and the terms of sale set out the only terms on which LIV MORE LLC supplies research material. Storage and delivery are covered on the shipping and returns page, and recurring documentation questions are answered in the site FAQ.

To see how these fields appear on a real document, open the tirzepatide entry in the Lot Passport and check each item above against the record for that batch.

Frequently asked questions